NSD1 and acute myeloid leukemia: Additionally, a novel NUP98-NSD1 siRNA-LNP formulation was validated as an effective treatment strategy for NUP98-NSD1-positive AML, supporting the preclinical and clinical development of this treatment approach to improve the outcome of NUP98-NSD1-positive AML patients.